A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA, in Treatment-Naïve HIV Infected Patients.

Trial Profile

A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA, in Treatment-Naïve HIV Infected Patients.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms QDMRK
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Sep 2014 Results of a racial subgroup analysis on the efficacy and safety of raltegravir presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top